RCUS
Arcus BiosciencesDNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Operating peers and competitors
Source-backed product markets and frozen research comparisons. Valuation comparators remain in the existing peer table.
Loading market evidence...
Research comparisons do not establish forecast usefulness or trading returns.
Compare shared product markets
Membership only; no portfolio weights or estimated losses.
+
Peers tracked
10
U.S. public peers
Grade Position
Below peers
vs peer average
RCUS vs peer average
36/100
RCUS vs. peer average (D vs. C)
Grade spread
A 2 · B 1 · C 3 · D 2 · F 2
Graded peers loaded
Coverage
10 graded
100% of tracked
Peer overview
EXEL is the first available peer comparator.
Treatment comparator: cabozantinib is the control regimen in Arcus's PEAK-1 trial; EXEL is a clinical benchmark, not a close valuation peer.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
RCUS
Arcus Biosciences
EXEL
Exelixis
Grade
D
C
Momentum
10
94
Value
41
65
Sentiment
51
32
Setup Bias
Net —
-
Market Cap
-
-
Posture
Defensive
Mixed
Grade position vs EXEL
RCUS / EXEL
Grade Position
Below peers
RCUS vs. peer average (D vs. C)
36/100
Momentum
10
EXELValue
41
EXELSentiment
51
RCUSRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs RCUS
EXEL is the first peer returned for this comparison set.